参一胶囊联合FOLFOX4方案治疗晚期胃癌的临床研究

目的观察参一胶囊联合FOLFOX4方案化疗治疗晚期胃癌（HI、IVY）的疗效及毒副反应。方法将93例晚期胃癌患者按照治疗方案不同随机分为两组：对照组单纯接受FOLFOX4方案化疗（53例），治疗组在化疗同时联合应用参一胶囊（40例）。结果对照组、治疗组近期客观疗效（完全缓解＋部分缓解）分别为57．5％和45．3％，差异无统计学意义（P〉0．05），治疗组血液学毒性发生率低于对照组（P〈0．05），在生活质量改善方面两组差异有统计学意义（P〈0．05）。结论晚期胃癌患者化疗后联合应用参一胶囊是一种新的安全有效的治疗方法，可减轻化疗毒副反应，改善患者生活质量。

Objective To study the effect of the combination of FOLFOX4 regimen and ginsenoside Rg3 capsules in treating advanced gastric carcinoma patients. Methods 93 patients in stage Ⅲ and Ⅳ had been treated with 4 cycles chemotherapy. They were randomized into two groups. The therapeutic group was treated by FOLFOX4 regime plus ginsenoside Rg3 20 mg bid po. The control group was treated by FOLFOX4 regime. Results The quality of life and survival of the patients were raised in therapeutic group. Conclusions This experiment suggests a new safe therapeutic antieancer paradigm for eontrolling gastric cancer, which improves the living quality and survival rate of patient with cancer.